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Abstract
Backgrounds: B3 adrenoreceptors (ADRB3) are abundant in adipose tissue and play the role in its metabolism and
lipolysis. Some variants of the ADRB3 gene may predispose subjects for the development obesity and metabolic
abnormalities in the setting of modern sedentary lifestyle. ADRB3 gene polymorphism association with metabolic
disturbances has never been studied before in the ethnic Kyrgyz population.
Aim: To study an association between Trp64Arg polymorphism of the ADRB3 and metabolic syndrome (MS)
components in an ethnic Kyrgyz group.
Materials and methods: 213 Ethnic Kyrgyz volunteers over the age of 30 were enrolled in the study. The
assessment plan for each individual comprised of general physical and anthropometric exams as well as laboratory
tests (glucose, lipid panel, insulin) and genotyping by Trp64Arg polymorphism of the ADRB3. MS diagnosis was
consistent with modified ATP III criteria (2005). Logistic regression analysis was performed to test the potential
independent association between Arg64 allele with obesity, abdominal obesity (AO) and arterial hypertension (AH).
Results: Trp64Arg polymorphism of the ADRB3 was assessed in 213 individuals (145 men, 68 women) aged 30-73
(mean age 50.7 ± 7.6). Arg64 allele frequency was 0.239; ADRB3 genotype distribution among participants was:
Trp64 homozygotes 54.5%, Trp64Arg 43.2% and Arg64 homozygotes 2.3%. There was an association between
Trp64Arg и Arg64Arg genotypes and higher BMI, WC and obesity frequency (p < 0.00009), AO (p < 0.01), type 2
diabetes mellitus (DM) (p < 0.005) and lower high density cholesterol (HDL-C) level (p < 0.03). The logistic
regression analysis showed the correlation of the Arg64 allele with obesity (OR 3.159; 95% CI 1.789-5.577) and AO
(OR 1.973; 95% CI 1.118-3.481). The association between Arg64 allele and AH lost its significance after adjustment
for obesity.
Conclusion: Arg64 allele of the ADRB3 gene in the studied group has an association with MS components such as
obesity, AO and decreased HDL-C level.
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Introduction
Changes in lifestyle of the world’s population, which
include increased intake of high-calorie food together
with low physical activity, promote the rising prevalence
of metabolic syndrome (MS), consisting of such risk fac-
tors as glucose metabolism abnormalities, dyslipidemia,
arterial hypertension (AH) and obesity [1]. The presence
of MS substantially increases the risk of the subsequent
development of cardiovascular diseases [2] and type 2
diabetes mellitus [3] (DM).
Genetic predisposition plays a crucial role in the
development of obesity besides traditionally acknowl-
edged risk factors such as overeating and a sedentary
lifestyle. Attempts to identify genes responsible for obe-
sity were focused mostly on white and brown adipose
tissues [4], which play an essential role in the regulation,
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mulation of the ADRB3, which are abundant in visceral
adipose tissue [8], activates adenylatecyclase, which in
turn increases the amount of intracellular cAMP and
thus causes enhanced lipolysis in white adipose tissue
and free fatty acids delivery to the portal vein [9]. Thus,
ADRB3 gene expression plays an important role in lipo-
lysis [10].
Theoretically the functional alterations in ADRB3 may
promote the development of obesity and insulin resis-
t a n c e( I R )[ 1 1 , 1 2 ] .M i s s e n s em u t a t i o ni nt h eA D R B 3
causes the substitution of the coding sequences from
tryptophan into arginine in 64
th position, and this point
mutation is able to influence receptor’s affinity to nore-
pinephrine and its interaction with Gs proteins in adipo-
cytes [13]. Some studies had shown the associations
between Arg64 variant of the ADRB3 gene and early
development of type 2 DM and decreased early insulin
response to glucose load [14], and, some studies with
cellular transfection had shown an association with
decreased glucose dependent insulin secretion [15].
Thereby ADRB3 gene is involved either directly or
indirectly in lipid and glucose metabolism processes and
may influence on endogenous energy balance and body
mass regulation. At the same time, data about Trp64Arg
polymorphism of the ADRB3 association with MS are
inconsistent. Thus, approximately half of the studies
found a positive association of the Trp64Arg poly-
morphism of the ADRB3 gene with obesity and IR
[13,16-19], whereas the other studies didn’tf i n da n y
relationships between the presence of such polymorph-
ism and obesity, type 2 DM or AH [20-22]. Such discor-
dant results may be partially explained by ethnicity, age,
or population differences in studied samples.
Previously Trp64Arg polymorphism of the ADRB3
gene had not been studied in the Kyrgyz population.
The aim of this work was to study a possible association
between this genetic polymorphism and MS compo-
nents in an ethnic Kyrgyz group.
Materials and methods
Study population
Inclusion criteria: ethnic Kyrgyz people over 30 years of
age who were permanent residents at the time, non con-
sanguine to each other, and willing to participate in the
study.
Exclusion Criteria: surgical intervention within a
month prior to study enrollment, severe kidney and/or
liver disease, thyroid dysfunction, alcohol abuse, treat-
ment with insulin, hypolipidemic and corticosteroid
medications, pregnancy and lactation.
National Center of Cardiology and Internal Medicine
and Kyrgyz State Medical Academy Ethics Committee
approved the study protocol. All participants were
informed about the aim and study protocol and gave
written consent prior to enrollment.
Finally, 213 volunteers (145 men and 68 women) aged
30-73 (mean age 50.7 ± 7.6) years were included in the
study.
All subjects completed the medical examination. Blood
pressure (BP) was measured using standard sphygmo-
manometer in the sitting position after a 10 minute rest.
Anthropometric data included body mass index (BMI)
a saw e i g h t( k g )t oh e i g h t( m
2) ratio, waist circumfer-
ence (WC) and hip circumference (HC) measurements.
Modified Adult Treatment Panel III criteria were used
for the MS diagnosis. [1].
Laboratory tests
Blood collection from the cubital vein took place after
12 hours of fasting in the morning. Laboratory tests
included fasting plasma glucose (FPG), lipid panel (total
cholesterol (TC), triglycerides (TG), high density lipo-
protein cholesterol (HDL-C)) and immunoreactive insu-
lin levels. Low density lipoprotein cholesterol (LDL-C)
was calculated by Friedwald W. formula [23]. IR index -
HOMA was calculated as serum insulin(μIU/ml)x
plasma glucose (mmol/l)/22.5. HOMA index ≥2.77 was
considered as IR presence. Lipid panel analysis was per-
formed on «Sinhron CX4-DELTA» biochemical autoa-
nalysator («Beckman», USA).
Genotyping
Genetic tests included DNA extraction with subsequent
determination of Trp64Arg polymorphism of the
ADRB3 gene. DNA was extracted from blood cells using
«Nucleon BACC3» kit ("Amersham Pharmacia Biotech”,
Sweden). Trp64Arg of the ADRB3 polymorphism was
detected using Restriction Fragment Length Polymorph-
ism (RFLP) method. Polymerase chain reaction (PCR)
was carried out on “Hybaid” amplificator (HBPX 220,
Great Britain) with specific primers (F - CGCCCAA-
TACCGCCAACAC and R - 3 CCACCAGGAGTCC-
CATCACC) and subsequent restriction of received PCR
products by «BstOI» enzyme («Promega», USA). The
received restriction fragments - Arg 64Arg 161 n.p.,
Trp64Arg 161+99+62 n.p., Trp64Trp np. were divided
by electrophoresis in 3% Agar gel. Gel scanning and
analysis of received results were made on image-densit-
ometer «Fluor-S Multimager» ("Bio-Rad”, USA).
Statistical analysis
The “SPSS v. 17.0” and “Graph Pad PRIZM 5” software
were used for statistical analyses. Student t test and
M a n n - W h i t n e yU-t e s tw e r eu s e dt oa s s e s sd i f f e r e n c e s
between continuous variables with normal and nonpara-
metric distribution respectively. The x
2 test was carried
out to study an association between categorical
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deviation (sd) for variables with normal distribution and
median (25th and 75th percentile) for variables with
nonparametric distribution. The logistic regression ana-
lysis was performed to test the potential independent
association between Arg64 allele and obesity, AO, type
2 DM and AH. The p value < 0.05 was considered as a
cut off for statistical significance.
Results
ADRB3 genotypes were found to be in Hardy-Weinberg
equilibrium. The frequency of Arg64 allele was 0.239
(0.269 and 0.176 in men and women respectively),
ADRB3 genotype distribution forTrp64 homozygotes,
Trp64Arg heterozygotes and Arg64 homozygotes were
54.5% (n = 116), 43.2% (n = 92) and 2.3% (n = 5)
respectively. The Arg64Arg was rarely present in this
sample, so all carriers of Arg64 allele were united in one
group.
General characteristics of the included participants are
present in Table 1.
Both groups were matched for age and smoking sta-
tus, but it is noteworthy that there were more males in
the Group #2. Obesity (p < 0.00009) and AO (p < 0.01)
were more prevalent in Trp64Arg and Arg64Arg geno-
types, rather than in Trp64Trp genotype. Thus, BMI,
WC and waist to hip ratio (WC/HC) were higher in the
Group 2 (Table 1). Comparative associations of the
ADRB3 genotypes with obesity parameters are present
in the Figure 1.
AH and type 2 DM also were more frequent in the
second group, but the differences in systolic and diasto-
lic BP and fasting glucose plasma level between the two
groups were not statistically significant. Individuals from
Group #2 comparing to the Trp64Trp genotype carriers
had a trend towards higher insulin levels and higher fre-
quency of IR and MS, but aforementioned parameters
did not reach statistical significance (table 2).
Lipid profile components except the HDL-C level
were approximately identical among both groups. HDL-
C level was lower in Arg64 allele carriers (p < 0.03).
Comparative associations of the ADRB3 genotypes with
HDL-C level are present in the Figure 2.
The results of x
2 tests demonstrated the positive asso-
ciation between carrying the Arg64 allele and main MS
components such as obesity (x
2 = 17.49; p < 0.0001),
abdominal obesity (AO) (x
2 = 5.56; p < 0.018), AH (x
2 =
5.5; p < 0.019) and type 2 DM (x
2 = 7.8; p < 0.0053)
(table 3).
In a forward stepwise logistic regression model that
included obesity as a dependent variable and the poly-
morphism of the ADRB3 (with Trp64 allele as refer-
ence) and sex as independent variables, only the
presence of the Arg64 allele reached statistical signifi-
cance (OR 3.16; 95% CI 1.79-5.56). In the same regres-
sion model with AO as the dependent variable the
similar results were obtained (OR 1.97; 95% CI 1.12-
3.48). For AH and type 2 DM after including only sex
and polymorphism of the ADRB3 as independent vari-
ables the Arg64 allele increased the odds ratio for AH
(OR 1.92; 95% CI 1.1-3.6) and for type 2 DM (OR 2.85;
95% CI 1.34-6.06), but after adjusting for obesity the
role of Arg64 allele lost its statistical significance in
both models.
Discussion
In this study, we found that among ethnic Kyrgyz peo-
ple the Trp64Trp genotype was more frequent and was
discovered in 116 studied persons (54.5%). The
Arg64Arg genotype was present only in 5 participants.
The presence of Arg64 allele in our study showed a
strong association with obesity and AO as well as
greater WC and BMI, even after adjustment for gender.
It is well known that obesity is one of the most impor-
tant risk factors for type 2 DM development, reflecting
not only severity and duration of obesity, but also fat
distribution [3]. From a theoretical point of view, it
seems plausible that altered function of ADRB3 may
promote the development of obesity through enhanced
lipid accumulation in white adipose tissue and decreased
biological energy expenditure from brown adipose tissue
as a result of decreased lipolysis [18,19]. It was shown
that ADRB3 mRNA is abundantly present in visceral
adipose tissue, compared with subcutaneous fat [9].
Table 1 General characteristics of studied patients and
correlation with risk factors:
Parameters Group #1
Trp64Trp
(n = 116)
Group # 2
Trp64Arg + Arg64Arg
(n = 97)
P
Sex (Male) 59% 78% 0.004
Age, years 51.0 ± 7.9 50.4 ± 7.3 ns
Obesity, % 29 55.2 0.00009
BMI, kg/m
2 27.7 ± 4.5 29.4 ± 4.9 0.008
AO, % 54.3 70.1 0.01
WC, cm 94.9 ± 13.2 101.7 ± 14 0.0004
WC/HC 0.95 ± 0.13 1.0 ± 0.14 0.028
AH, % 32.7 48.5 0.019
SBP, mmHg 134.3 ± 23.4 136.1 ± 24.1 ns
DBP, mmHg 84.8 ± 13.6 87.1 ± 13.2 ns
Type 2 DM, % 10.3% 24.7% 0.005
Fasting glycemia 5.9 ± 1.9 6.05 ± 2.02 ns
Smoking, % 24.7 25 ns
IR, % 21.3%(n = 80) 28.3% (n = 46) ns
MS, % 37.9% 49.5% ns
ns -non significant;
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Page 3 of 7Diminished lipid oxidation may serve as a predictor of
subsequent increase of fat amount in the human organ-
ism [24]. Some studies had shown associations between
obesity and Trp64Arg polymorphism of the ADRB3
gene [25], but not others [26,27]. In studies focused on
ADRB3 gene polymorphism and BMI, there was a stron-
ger association between in Asian population, compared
to Caucasians [28,29]. The Chinese researchers had
shown that ADRB3 R64 allele was associated with
increased BMI and weight [30] and research group from
Poland had found the protective effects of the ADRB3
Arg64 polymorphism against metabolic disorders [31].
Results of the studies focused on Trp64Arg carrier
state association with MS are also controversial. Some
found a correlation between this polymorphism and
body weight and BMI variables [32], whereas others
detected that W64 allele homozygotes of the ADRB3 are
relatively protected against metabolic abnormalities [30].
I nt h eQ u e b e cF a m i l yS t u d yr e s e a r c h e r sd i dn o tf i n d
any differences in glucose, insulin levels and BP values
in studied groups with and without Arg64 allele [22].
Japanese researchers found ADRB3 polymorphism asso-
ciation with IR, but not with dyslipidemia [33]. Also
prior investigations did not find statistically significant
relationships between ADRB3 genotype and type 2 DM
[13,17,34]. Nevertheless it reached statistical significance
in the meta analysis performed by Fujisawa T et al. [33].
In our study the frequency of type 2 DM in Trp64Arg
and Arg64Arg group was higher but the association lost
its significance after adjustment for obesity.
Experimental data clearly shows that, besides its effect
on lipolysis and biological energy production, ADRB3
may modulate peripheral vascular tone and increase the
BP [35]. Some clinical studies pointed on possible rela-
tionship between AH and Trp64Arg polymorphism
[17,35,36], as well as relationship between this genotype
and higher mortality among hypertensives [37]. In our
study, we found an association of Trp64Arg carrier state
with AH (p < 0.019). After logistic regression analysis,
including gender and ADRB3, the association was still
statistically significant, but after including obesity in the
list, ADRB3 lost its significance. It seems that AH as
well as most other disorders are polygenic in nature
where many genes and environmental factors play a role
i nt h ep a t h o g e n e s i s .I tm a yb es p e c u l a t e dt h a tA r g 6 4
allele may indirectly affect AH risk through the develop-
ment of obesity. In a recently published Japanese work
Table 2 Laboratory test results and relationship with MS
and IR.
Parameters Group #1
Trp64Trp
(n = 116)
Group #2
Trp64Arg + Arg64Arg
(n = 97)
P
TC, mmol/l 5.14 ± 1.08 4.92 ± 0.9 ns
LDL-C, mmol/l 3.23 ± 0.92 3.12 ± 0.8 ns
HDL-C, mmol/l 1.12 ± 0.34 1.02 ± 0.33 0.03
TG, mmol/l 1.36(0.92; 2.1) 1.42 (1.08; 2.22) ns
Insulin, μIU/ml 6.65 (4.8; 9.89) (n = 80) 8.28(4.24; 11.8)
(n = 46)
ns
ns -non significant
0
10
20
30
40
50
60
70
80
90
100
Obesity Abdominal
Obesity
Trp64Trp
Trp64Arg+Arg64Arg
*p<0.05 
% 
*p<0.05 
Figure 1 ADRB3 genotypes and obesity parameters.
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Page 4 of 7it was clearly shown that Trp64Arg polymorphism is
associated with cardiovascular risk among hypertensive
[31]. Besides the ADRB3, some genetic variants of the
cardiac B 1 adrenoreceptor may play a role in the devel-
opment of left ventricular hypertrophy in patients after
acute coronary event in patients without DM or AH
[38]. This highlights the possibility of altered sympa-
thetic signaling in the pathogenesis of cardiovascular
disease.
Data on the ADRB3 gene mutation effect on lipid
metabolism are inconsistent and heterogeneous. Some
studies did not find any correlation between Arg64
allele and serum lipids [17,22]. On the other hand, a
study conducted on a young Danish population
showed, that this mutation had an associations with
hypertriglyceridemia and increased LDL-C levels [39].
Recently published data in Spain about Trp64Arg car-
rier state in hypertensive cohort had shown associa-
tions with higher BMI and TC level [40]. In our
sample, Trp64Arg carriers had lower HDL-C levels,
but other cholesterol metabolism parameters did not
reach statistical significance.
Table 3 Trp64Trp, Trp64Arg and Arg64Arg genotypes of the B3AR gene and their correlation with AO, AH and DM
type 2.
Trp64Trp,n(%), n = 116 Trp64Arg andArg64Arg,
n (%), n = 97
x
2;p
Obesity:
yes 34 (29.3) 56 (57.7) x
2 = 17.49; p < 0.0001
no 82 (70.7) 41 (42.3)
AO:
yes 63 (54.3) 68(70.1) x
2 = 5.56; p = 0.018
no 53 (45.7) 29 (29.9)
AH:
yes 39 (33.6) 48 (49.5) x
2 = 5.5; p = 0.019
no 77 (66.4) 49 (50.5)
DM 2:
yes 12 (10.3) 24 (24.7) x
2 = 7.8; p = 0.0053
no 104 (89.7) 73 (75.3)
0
0.2
0.4
0.6
0.8
1
1.2
Trp64Trp*T r p64Arg+Arg64Arg*
mmol/l 
*P<0.05 
Figure 2 ADRB3 and HDL-C level.
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Page 5 of 7Conclusion
Our work was the first in studying Trp64Arg poly-
morphism among ethnic Kyrgyz people, where we found
an association of this ADRB3 gene polymorphism with
components of MS, such as obesity, AO, and decreased
HDL-C level. This study and its findings may be useful
and provide some basic information regarding our
understanding of complex pathological interconnections
between metabolic heritage and modern environment.
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